Evidence map›Paper›PMID 38024451›Full record

ArticleInternational journal of pharmaceutics: X2023

Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics,

Shereen Nader Raafat, Sara Abd El Wahed, Noha M Badawi, Mona M Saber, Maha R A Abdollah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024
    Review
  8. Research Progress on the Use of Metformin in Leukemia Treatment.Current treatment options in oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shereen Nader RaafatDepartment of Pharmacology, Faculty of Dentistry, The British University in Egypt, Cairo, Egypt.
Sara Abd El WahedDepartment of Oral Pathology, Faculty of Dentistry, The British University in Egypt, Cairo, Egypt.
Noha M BadawiDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.
Mona M SaberDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
Maha R A AbdollahCenter for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt, El Sherouk City, Egypt.
British University in Egypt · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin (MET), an oral antidiabetic drug, was reported to possess promising anticancer effects. We hypothesized that MET encapsulation in unique nanospanlastics would enhance its anticancer potential against HEP-2 cells. Our results showed the successful fabrication of Nano-MET spanlastics (d = 232.10 ± 0.20 nm; PDI = 0.25 ± 0.11; zeta potential = (-) 44.50 ± 0.96; drug content = 99.90 ± 0.11 and entrapment efficiency = 88.01 ± 2.50%). MTT assay revealed the enhanced Nano-MET cytotoxicity over MET with a calculated IC

Indexed as

HEP-2 cellsMetforminNanovesiclesReactome analysisSpanlastics

Identifiers

PMID38024451
PMCPMC10630776
OpenAlexW4387873494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.